Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CAPR 
Capricor Therapeutics Inc (CAPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CAPR (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $20.6
1 Year Target Price $20.6
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 59% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 286.19M USD | Price to earnings Ratio - | 1Y Target Price 20.6 |
Price to earnings Ratio - | 1Y Target Price 20.6 | ||
Volume (30-day avg) 8 | Beta 0.59 | 52 Weeks Range 3.98 - 23.40 | Updated Date 08/28/2025 |
52 Weeks Range 3.98 - 23.40 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.48 | Actual -0.57 |
Profitability
Profit Margin - | Operating Margin (TTM) -548.16% |
Management Effectiveness
Return on Assets (TTM) -53.4% | Return on Equity (TTM) -120.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 163974520 | Price to Sales(TTM) 21.37 |
Enterprise Value 163974520 | Price to Sales(TTM) 21.37 | ||
Enterprise Value to Revenue 12.24 | Enterprise Value to EBITDA -2.73 | Shares Outstanding 45717000 | Shares Floating 40185221 |
Shares Outstanding 45717000 | Shares Floating 40185221 | ||
Percent Insiders 16.79 | Percent Institutions 30.49 |
Upturn AI SWOT
Capricor Therapeutics Inc
Company Overview
History and Background
Capricor Therapeutics Inc. was founded in 2005. It is a biotechnology company focused on developing and commercializing cell and exosome-based therapeutics for severe diseases. Their initial focus was on cardiovascular disease, but they have expanded into other areas.
Core Business Areas
- CAP-1002 (Cell Therapy): CAP-1002 is an allogeneic cardiac-derived cell therapy candidate being developed for the treatment of Duchenne muscular dystrophy (DMD) and other potential indications. It aims to modulate the immune system and improve cardiac and skeletal muscle function.
- Exosome Platform: Capricor is developing a proprietary exosome technology platform for therapeutic and diagnostic applications. This platform is aimed at delivering therapeutic payloads to specific cells or tissues.
Leadership and Structure
Linda Marbu00e1n, Ph.D. is the President and CEO. The company has a typical organizational structure for a publicly traded biotechnology company, with departments focused on research and development, clinical trials, regulatory affairs, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- CAP-1002 (DMD): CAP-1002 is their lead product candidate currently in clinical development for Duchenne Muscular Dystrophy (DMD). Market share data for future potential revenue is dependent on FDA approval. Competitors include Sarepta Therapeutics (SRPT) with gene therapies, and steroids offering symptom management.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high risk and high reward. Companies are investing heavily in research and development to create innovative therapeutics. The market for DMD therapeutics is growing due to increasing awareness and improved diagnostic capabilities.
Positioning
Capricor is a clinical-stage biotechnology company focused on cell and exosome-based therapies. Their competitive advantage lies in their proprietary cell therapy technology and exosome platform.
Total Addressable Market (TAM)
The estimated TAM for DMD therapies is several billion dollars globally. Capricor's position within this market is dependent on the successful development and commercialization of CAP-1002.
Upturn SWOT Analysis
Strengths
- Proprietary cell therapy technology
- Exosome platform
- Experienced leadership team
- Orphan drug designation for CAP-1002 in DMD
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- Commercialization risks
- High cash burn rate
Opportunities
- Potential FDA approval of CAP-1002
- Expansion of exosome platform into new therapeutic areas
- Strategic partnerships and collaborations
- Government grants and funding opportunities
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other DMD therapies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- SRPT
- PTCT
Competitive Landscape
Capricor is a smaller player compared to Sarepta and PTC Therapeutics. Capricor's advantage lies in its unique cell therapy approach, but faces competition from gene therapies and other DMD treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by clinical trial progress and partnerships. The stock price can be volatile due to news flow around clinical trial data.
Future Projections: Future growth is dependent on the successful development and commercialization of CAP-1002 and other pipeline candidates. Analyst estimates should be consulted for specific projections.
Recent Initiatives: Recent initiatives include advancing CAP-1002 through clinical trials, expanding the exosome platform, and seeking strategic partnerships.
Summary
Capricor Therapeutics is a clinical-stage biotech with potential in DMD therapy, primarily CAP-1002. Its success depends on clinical trial outcomes and regulatory approval, posing risks due to high R&D costs and competition. Key strengths include its proprietary technologies; weaknesses are limited resources and financial dependence. Future growth is linked to successful commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data, which may be subject to change. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Capricor Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2007-02-13 | Co-Founder, President, CEO & Director Dr. Linda Marbán Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 160 | Website https://www.capricor.com |
Full time employees 160 | Website https://www.capricor.com | ||
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.